^
    Back
    Association details:
    Biomarker:EZH2 deletion
    Cancer:Multiple Myeloma
    Drug:pifusertib (TAS-117) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ASH 2019
    Title:

    Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

    Published date:
    11/06/2019
    Excerpt:
    Importantly, EZH1 knockdown significantly enhanced the sensitivity of myeloma cells to TAS-117-induced cytotoxicity.
    DOI:
    https://doi.org/10.1182/blood-2019-122157